Boron-containing small molecules

Patent metadata

Field	Value
Publication number	US-10611780-B2
Application number	US-201716081902-A
Country	US
Kind code	B2
Filing date	Feb 27, 2017
Priority date	Mar 2, 2016
Publication date	Apr 7, 2020
Grant date	Apr 7, 2020

Abstract

Compounds, pharmaceutical formulations, and methods of treating bacterial infections are disclosed.

First claim

What is claimed is:

1. A compound, or a salt or a hydrate or a solvate thereof, having a structure which is:

wherein
X is H or F or OH;
Y is selected from the group consisting of a bond, —O—, —S—, —NH—, alkylene, and heteroalkylene; and
Z is a heterocyclic ring or ring system containing at least one endocyclic boron.

2. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein said Y is *—OCH 2 — or *—SCH 2 — or *—NHCH 2 — or *—CH 2 NH— or *—C(O)NH—, wherein * represents the point of attachment to said Z.

3. The compound of claim 1 , or a salt or a hydrate or a solvate thereof, wherein said Z is selected from the group consisting of benzoxaborole, pyridinyloxaborole, benzoxaborininol, benzoxazaborininol, benzodiazaborininol, oxaborole, and dihydrobenzoazaborinine.

4. The compound of claim 3 , or a salt or a hydrate or a solvate thereof, wherein said Z is

wherein
R 3 , R 3a , R 4 , R 5 , and R 7 are each independently selected from the group consisting of R 10 , —OR 10 , —NR 10 R 11 , —SR 10 , —S(O)R 10 , —S(O) 2 R 10 , —S(O) 2 NR 10 R 11 , —C(O)R 10 , —C(O)OR 10 , and —C(O)NR 10 R 11
wherein
R 10 and R 11 are each independently selected from the group consisting of H, halogen, cyano, nitro, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

5. A selected from the group consisting of (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-((7-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)oxy)acetate, (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl (7-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)glycinate, (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl ((7-fluoro-1-hydroxy-1,3-dihydrobenzo[c][1,2]oxaborol-6-yl)methyl)carbamate, (3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl 2-((1-hydroxy-1H-benzo [d][1,2,6] oxazaborinin-7-yl)oxy)acetate, and methyl 1-hydroxy-7-(2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanocyclopenta[8]annulen-5-yl)oxy)-2-oxoethoxy)benzo[d][1,2,3]diazaborinine-2(1H)-carboxylate, or a salt or a hydrate or a solvate thereof.

6. The compound of claim 3 , or a salt or a hydrate or a solvate thereof, wherein said Z is

wherein
R 3 , R 4 , R 5 , and R 7 are each independently selected from the group consisting of R 10 , —OR 10 , —NR 10 R 11 , —SR 10 , —S(O)R 10 , —S(O) 2 R 10 , —S(O) 2 NR 10 R 11 , —C(O)R 10 , —C(O)OR 10 , and —C(O)NR 10 R 11
wherein
R 10 and R 11 are each independently selected from the group consisting of H, halogen, cyano, nitro, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

7. The compound of claim 3 , or a salt or a hydrate or a solvate thereof, wherein said Z is

wherein
R 1 , R 4 , R 5 , and R 7 are each independently selected from the group consisting of R 10 , —OR 10 , —NR 10 R 11 , —SR 10 , —S(O)R 10 , —S(O) 2 R 10 , —S(O) 2 NR 10 R 11 , —C(O)R 10 , —C(O)OR 10 , and —C(O)NR 10 R 11
wherein
R 10 and R 11 are each independently selected from the group consisting of H, halogen, cyano, nitro, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl.

8. A combination comprising the compound of claim 1 , or a pharmaceutically acceptable salt or a hydrate or a solvate thereof, together with at least one other therapeutically active agent.

9. A pharmaceutical formulation comprising:
a) the compound of claim 1 , or a pharmaceutically acceptable salt or a hydrate or a solvate thereof; and
b) a pharmaceutically acceptable excipient.

10. A method of inhibiting protein synthesis in a bacteria, the method comprising contacting the bacteria with the compound of claim 1 , or a pharmaceutically acceptable salt or a hydrate or a solvate thereof, thereby inhibiting protein synthesis in the bacteria.

11. A method of inhibiting the growth of and/or killing a bacteria, the method comprising contacting the bacteria with the compound of claim 1 , or a pharmaceutically acceptable salt or a hydrate or a solvate thereof, thereby inhibiting the growth of and/or killing the bacteria.

12. A method of treating a disease associated with a Gram-positive, Gram positive bacteria, and/or a worm in an animal, the method comprising administering to the animal a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt or a hydrate or a solvate thereof, thereby treating the disease.

13. The method of claim 12 , wherein the disease is selected from the group consisting of pneumonia, hospital-acquired pneumonia, hospital-associated pneumonia, community-acquired pneumonia, acute bacterial skin and skin-structure infection (ABSSSI), bacteremia, endocarditis, osteomyelitis, gastroenteritis, toxic shock syndrome, meningitis, septic arthritis, urinary tract infection, skin and skin-structure infection, strep throat, necrotizing fasciitis, otitis media, sinusitis, actinomycosis, diptheria, anthrax, food poisoning, botulism, tetanus, gas gangrene, diarrhea, tuberculosis, leprosy, candidiasis, aspergillosis, coccidioidomycosis, cryptococcosis, histoplasmosis, blastomycosis, paracoccidioidomycosis, zygomycosis, phaeohyphomycosis, rhinosporidiosis, enterobiasis, filariasis, lymphatic filariasis, bancroftian filariasis, subcutaneous filariasis, serious cavity filariasis, elephantiasis, elephantiasis tropica, lymphadenitis, lymphangitis, lymphedema, and onchocerciasis.

Assignees

• Anacor Pharmaceuticals Inc
• Bill And Melinda Gates Found
• Zhang Yong Kang
• Perry Matthew
• Li Xianfeng
• Lunde Christopher S
• Jacobs Robert T
• Hernandez Vincent S
• Xia Yi
• Plattner Jacob J
• Cao Kathy Jingyuan

Inventors

• Li Xianfeng
• Lunde Christopher S
• Jacobs Robert T
• Hernandez Vincent S
• Xia Yi
• Plattner Jacob J
• Cao Kathy Jingyuan
• Zhang Yong-Kang
• Perry Matthew

Classifications

• A61P31/04

  Antibacterial agents · CPC title

• C07F5/025 Primary

  Boronic and borinic acid compounds · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• C07F5/02

  Boron compounds · CPC title

• A61K31/69

  Boron compounds · CPC title